Arthneeti
BD

Beta Drugs Ltd

Q1 FY27Pharmaceuticals & Biotechnology

Beta Drugs Ltd Q1 FY27 Results & Presentation Highlights: Revenue, Margins & Order Book

Q1 FY27 investor presentation: what the company reported on revenue, margins and projects.

Price₹2,093
Market cap₹2.3K Cr
P/E50.0
Updated24 Sept 2026
Read4 min read

Based on Beta Drugs Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

Q1-FY27 revenue from operations: INR 1,255 Mn, up 25.2% YoY from INR 1,002 Mn in Q1-FY26 (Page 32). Q1-FY27 EBITDA: INR 274 Mn, up 39.1% YoY (from INR 197 Mn in Q1-FY26); EBITDA Margin: 21.83%, up 217 bps YoY (from 19.66% in Q1-FY26) - Q1-FY27 PAT: INR 165 Mn, up 41.0% YoY (from INR 117 Mn in Q1-F

From Beta Drugs Ltd's Q1 FY27 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q1-FY27 revenue from operations: INR 1,255 Mn, up 25.2% YoY from INR 1,002 Mn in Q1-FY26 (Page 32).
  • EBITDA for Q1-FY27: INR 274 Mn, +39.1% YoY (Page 32).
  • PAT for Q1-FY27: INR 165 Mn, +41.0% YoY (Page 32).
  • Branded Oncology business grew 47% YoY, sales INR 330 Mn (Page 31).
  • Contract Manufacturing (CMO) grew 41% YoY (Page 31).
  • Exports revenue in Q1-FY27: INR 172 Mn (Page 30).
  • Domestic Branded Formulations revenue contribution was 36% for FY26; Nivian IVF revenues consolidated from FY27 (Page 5).

2 more points management made on revenue & sales performance

Profitability & Margins

See what Beta Drugs Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

The presentation mentions the following capex, capacity expansion, and new projects: - **EU GMP-aligned Infrastructure Expansion**: Part of export expansion strategy to support dossier filings, product registration, and deeper market penetration (Page 23). - **Three WHO-GMP Certified Manufacturing Facilities**: Existing facilities with strong manufacturing capabilities, including one with additional accreditations (Page 22). - **API Manufacturing Infrastructure Expansion**: Modern API manufacturing capabilities supporting backward integration and cost-efficiency, with a focus on expanding API capabilities for global markets and future products (Page 20).

2 more points management made on capital expenditure plans

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1KRM Ayurveda Ltd
Rev 1Mar 1
2Accretion Pharmaceuticals Ltd
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Beta Drugs Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation for Beta Drugs Ltd. does not explicitly report specific figures for order book, order inflow, or pending orders. However, it provides insights related to business momentum and demand: - Export business generated INR 172 Mn revenue in Q1-FY27, with management expecting stronger momentum and accelerated order inflows over the remainder of FY27 (Page 31). - The Contract Manufacturing (CMO) business showed robust growth (41% YoY) supported by strong traction with customers and new launches (Page 31). - No explicit numbers or details of order book, order inflows, or pending orders are disclosed in the presentation. Thus, while there is mention of anticipated strong order inflows and business growth, exact details on order book or pending orders are not reported.

Beta Drugs Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024
Mar 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹94 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Beta Drugs Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Morepen Laboratories Ltd (Q1 FY27)

    575.31 Cr (Page 4) . Key investor presentation takeaways from Morepen Laboratories Ltd's Q1 FY27 investor presentation — and how it ranks against sector peers.

  • Procter & Gamble Health Ltd (Q1 FY27)

    FY 2025-26 sales grew by +16% year-on-year, indicating strong consistent balanced growth (Page 8). Key investor presentation takeaways from Procter & Gamble Hea

  • Jubilant Pharmova Ltd (Q1 FY27)

    2,229 Cr., up 17% YoY (Page 97) . Key investor presentation takeaways from Jubilant Pharmova Ltd's Q1 FY27 investor presentation — and how it ranks against sect

  • NGL Fine Chem Ltd (Q1 FY27)

    Quarterly Revenue (Q1FY27):** ₹139.16 crores . Key investor presentation takeaways from NGL Fine Chem Ltd's Q1 FY27 investor presentation — and how it ranks aga

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Beta Drugs Ltd Q1 FY27 results?

Q1-FY27 revenue from operations: INR 1,255 Mn, up 25.2% YoY from INR 1,002 Mn in Q1-FY26 (Page 32). Q1-FY27 EBITDA: INR 274 Mn, up 39.1% YoY (from INR 197 Mn in Q1-FY26); EBITDA Margin: 21.83%, up 217 bps YoY (from 19.66% in Q1-FY26) - Q1-FY27 PAT: INR 165 Mn, up 41.0% YoY (from INR 117 Mn in Q1-F

What is Beta Drugs Ltd share price analysis?

Beta Drugs Ltd currently shows a neutral. The stock trades at a P/E of 50.0 with a market cap of ₹2,278 Cr. Investors should review the full earnings analysis for detailed insights.

Is Beta Drugs Ltd planning capital expenditure?

The presentation mentions the following capex, capacity expansion, and new projects: - EU GMP-aligned Infrastructure Expansion: Part of export expansion strategy to support dossier filings, product registration, and deeper market penetration (Page 23).

Keep Beta Drugs Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.